Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 2
1998 1
2000 1
2008 1
2010 1
2011 1
2014 1
2017 1
2018 1
2019 1
2020 1
2021 4
2022 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ferre e (142 results)?
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Disseminated histoplasmosis: case report and review of the literature.
Evrard S, Caprasse P, Gavage P, Vasbien M, Radermacher J, Hayette MP, Sacheli R, Van Esbroeck M, Cnops L, Firre E, Médart L, Moerman F, Minon JM. Evrard S, et al. Among authors: firre e. Acta Clin Belg. 2018 Oct;73(5):356-363. doi: 10.1080/17843286.2017.1376454. Epub 2017 Sep 28. Acta Clin Belg. 2018. PMID: 28954600 Review.
[Acute kidney injury: from concept to practice].
Moonen M, Fraipont V, Radermacher L, Masset C, Firre E, Warling X. Moonen M, et al. Among authors: firre e. Nephrol Ther. 2011 Jun;7(3):172-7. doi: 10.1016/j.nephro.2010.11.005. Epub 2010 Dec 17. Nephrol Ther. 2011. PMID: 21168380 Review. French.
[Parathyroid carcinoma].
Longrée L, Massart B, Firre E, Lejeune A, Partoune E, Jardon-Jeghers C, Boniver J, Lejeune G. Longrée L, et al. Among authors: firre e. Rev Med Liege. 1989 Apr 1;44(7):272-9. Rev Med Liege. 1989. PMID: 2717837 French. No abstract available.
Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017.
Vandael E, Latour K, Goossens H, Magerman K, Drapier N, Catry B, Versporten A; Belgian Point Prevalence Survey Study Group. Vandael E, et al. Antimicrob Resist Infect Control. 2020 Jan 13;9(1):13. doi: 10.1186/s13756-019-0663-7. eCollection 2020. Antimicrob Resist Infect Control. 2020. PMID: 31956402 Free PMC article.
17 results